E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
beta-Alanine and gamma-aminobutyric acid in chronic fatigue syndrome.
Hannestad, Ulf, Theodorsson, Elvar, Evengård, Birgitta · Clinica chimica acta; international journal of clinical chemistry · 2007 · DOI
Quick Summary
Researchers measured two brain chemicals (GABA and beta-alanine) in the urine of ME/CFS patients and healthy people to see if abnormal levels might explain fatigue and sleep problems. They found no overall difference between patients and controls, but a small subgroup of ME/CFS patients (4 out of 33) had unusually high beta-alanine levels, suggesting this chemical imbalance might affect some—but not all—people with ME/CFS.
Why It Matters
This study highlights that ME/CFS may not be a single disease but rather a collection of different biological subtypes. Identifying a small subgroup with abnormal neurotransmitter metabolism could eventually lead to targeted treatments for specific patient subsets rather than one-size-fits-all approaches.
Observed Findings
- Men showed significantly higher excretion of both beta-alanine and GABA compared to women in both groups.
- No statistically significant difference in beta-alanine or GABA excretion was found when comparing all CFS patients to healthy controls.
- Four CFS patients (12% of the cohort) excreted notably elevated beta-alanine compared to control subjects.
- No correlation was found between beta-alanine or GABA excretion and symptom severity measured on Visual Analogue Scales.
Inferred Conclusions
- Beta-alanine metabolism may be abnormal in a subgroup of ME/CFS patients, suggesting biological heterogeneity within the disease.
- Male-female differences in neurotransmitter excretion may warrant investigation as a sex-based biological factor in ME/CFS.
Remaining Questions
- What distinguishes the four patients with elevated beta-alanine from other ME/CFS patients clinically and biologically?
- Does elevated beta-alanine excretion reflect a primary metabolic abnormality or a secondary consequence of ME/CFS pathophysiology?
- Would longitudinal tracking of these metabolites over time reveal changes related to disease progression or symptom fluctuation?
- Can findings be replicated in a larger, independent cohort?
What This Study Does Not Prove
This study does not prove that beta-alanine abnormalities cause ME/CFS symptoms, only that some patients may have elevated levels. The cross-sectional design means researchers cannot determine whether chemical changes are a cause, consequence, or coincidence. The findings apply to a tiny fraction of patients and require replication before drawing clinical conclusions.
Tags
Symptom:Unrefreshing SleepFatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlySex-Stratified
Metadata
- DOI
- 10.1016/j.cca.2006.07.004
- PMID
- 16934791
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →